Baird Increases Price Target for CVS Health Corporation
Baird has raised its price target for CVS Health Corporation (NYSE:CVS) from $92 to $94, maintaining an Outperform rating. The upgrade follows positive developments in CVS's financial performance and strategic initiatives, including improved operating income and EPS guidance for 2026.
Tickers: $CVS
Topics: Analyst Upgrade CVS Health Dividend Stocks Healthcare Stocks Price Target